Tumor-specific, hypoxia-regulated, WW domain-containing oxidoreductase-expressing adenovirus inhibits human non-small cell lung cancer growth in vivo

Human Gene Therapy

Volumn 21, Issue 1, 2010, Pages 27-39

  Zhang, Ping ^a   Ying, Lei ^a   Xu, Rang ^a   Ge, Shengfang ^a   Mei, Wenhan ^a   Li, Feng ^a   Dai, Bingbing ^a   Lu, Jian ^a   Qian, Guanxiang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; HYBRID PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LUCIFERASE; OXIDOREDUCTASE; OXYGEN DEPENDENT DEGRADATION DOMAIN CONTAINING HYPOXIA INDUCIBLE FACTOR 1ALPHA; RECOMBINANT ENZYME; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; WW DOMAIN CONTAINING OXIDOREDUCTASE;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER INHIBITION; CANCER SIZE; CELL HYPOXIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HYPOXIA; LUNG NON SMALL CELL CANCER; NONHUMAN; PROMOTER REGION; REPORTER GENE; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENES, REPORTER; HUMANS; LUNG NEOPLASMS; MICE; ORGAN SPECIFICITY; OXIDOREDUCTASES; PROMOTER REGIONS, GENETIC; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; TELOMERASE; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE;

EID: 74949117313     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2009.021     Document Type: Article

References (39)

1. Abdul-Ghani, R., Ohana, P., Matouk, I., Ayesh, S., Ayesh, B., Laster, M., Bibi, O., Giladi, H., Molnar-Kimber, K., Sughayer, M.A., de Groot, N., and Hochberg, A. (2000). Use of tran-scriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells. Mol. Ther. 2, 539-544.
2. Aqeilan, R.I., Palamarchuk, A., Weigel, R.J., Herrero, J.J., Pekarsky, Y., and Croce, C.M. (2004). Physical and functional interactions between the Wwox tumor suppressor protein and the AP-2gamma transcription factor. Cancer Res. 64, 8256-8261.
3. Bednarek, A.K., Laflin, K.J., Daniel, R.L., Liao, Q., Hawkins, K.A., and Aldaz, C.M. (2000). WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res. 60, 2140-2145.
4. Binley, K., Iqball, S., Kingsman, A., Kingsman, S., and Naylor, S. (1999). An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer. Gene Ther. 6, 1721-1727.
5. Blancher, C., and Harris, A.L. (1998). The molecular basis of the hypoxia response pathway: tumour hypoxia as a therapy target. Cancer Metastasis Rev. 17, 187-194.
6. Cecic, I., Chan, D.A., Sutphin, P.D., Ray, P., Gambhir, S.S., Giaccia, A.J., and Graves, E.E. (2007). Oxygen sensitivity of reporter genes: implications for preclinical imaging of tumor hypoxia. Mol. Imaging 6, 219-228.
7. Chan, D.A., Sutphin, P.D., Yen, S.E., and Giaccia, A.J. (2005). Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1 alpha. Mol. Cell Biol. 25, 6415-6426.
8. Chang, N.S. (2002). A potential role of p53 and WOX1 in mito-chondrial apoptosis (review). Int. J. Mol. Med. 9, 19-24.
9. Chang, N.S., Doherty, J., and Ensign, A. (2003). JNK1 physically interacts with WW domain-containing oxidoreductase (WOX1) and inhibits WOX1-mediated apoptosis. J. Biol. Chem. 278, 9195-9202.
10. Chang, N.S., Pratt, N., Heath, J., Schultz, L., Sleve, D., Carey, G.B., and Zevotek, N. (2001). Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. J. Biol. Chem. 276, 3361-3370.
11. Fabbri, M., Iliopoulos, D., Trapasso, F., Aqeilan, R.I., Cimmin, A., Zanesi, N., Yendamuri, S., Han, S.Y., Amadori, D., Huebner, K., and Croce, C.M. (2005). WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proc. Natl. Acad. Sci. USA 102, 15611-15616.
12. Frew, I.J., Minola, A., Georgiev, S., Hitz, M., Moch, H., Richard, S., Vortmeyer, A.O., and Krek, W. (2008). Combined VHLH and PTEN mutation causes genital tract cystadenoma and squamous metaplasia. Mol. Cell Biol. 28, 4536-4548.
13. Giatromanolaki, A., Koukourakis, M.I., Simopoulos, C., Poly-chronidis, A., Gatter, K.C., Harris, A.L., and Sivridis, E. (2004). c-erbB-2 related aggressiveness in breast cancer is hypoxia inducible factor-1alpha dependent. Clin. Cancer Res. 10, 7972-7977.
14. Greco, O., Joiner, M.C., Doleh, A., Powell, A.D., Hillman, G.G., and Scott, S.D. (2006). Hypoxia-and radiation-activated Cre=loxP "molecular switch" vectors for gene therapy of cancer. Gene Ther. 13, 206-215.
15. Gu, J., Andreeffm, M., Rothm, J.A., and Fang, B. (2002). hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity. Gene Ther. 9, 30-37.
16. Heise, C., Sampson-Johannes, A., Williams, A., McCormick, F., Von Hoff, D.D., and Kirn, D.H. (1997). ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3, 639-645.
17. Horikawa, I., Cable, P.L., Afshari, C., and Barrett, J.C. (1999). Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res. 59, 826-830. (Pubitemid 29086735)
18. Ido, A., Uto, H., Moriuchi, A., Nagata, K., Onaga, Y., Onaga, M., Hori, T., Hirono, S., Hayashi, K., Tamaoki, T., and Tsubouchi, H. (2001). Gene therapy targeting for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human alpha-fetoprotein promoter. Cancer Res. 61, 3016-3021.
19. Kim, H.A., Kim, K., Kim, S.W., and Lee, M. (2007). Transcrip-tional and post-translational regulatory system for hypoxia specific gene expression using the erythropoietin enhancer and the oxygen-dependent degradation domain. J. Control Release 121, 218-224.
20. Kirch, H.C., Ruschen, S., Brockmann, D., Esche, H., Horikawa, I., Barrett, J.C., Opalka, B., and Hengge, U.R. (2002). Tumor-specific activation of hTERT-derived promoters by tumor suppressive E1A-mutants involves recruitment of p300=CBP= HAT and suppression of HDAC-1 and defines a combined tumor targeting and suppression system. Oncogene 21, 7991-8000.
21. Koshikawa, N., Takenaga, K., Tagawa, M., and Sakiyama, S. (2000). Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells. Cancer Res. 60, 2936-2941.
22. Levy, A.P., Levy, N.S., Iliopoulos, O., Jiang, C., Kaplin, W.G., and Goldberg, M.A., Jr. (1997). Regulation of vascular endo-thelial growth factor by hypoxia and its modulation by the von Hippel-Lindau tumor suppressor gene. Kidney Int. 51, 575-578.
23. Liu, J., Harada, H., Ogura, M., Shibata, T., and Hiraoka, M. (2007). Adenovirus-mediated hypoxia-targeting cytosine de-aminase gene therapy enhances radiotherapy in tumour xe-nografts. Br. J. Cancer 96, 1871-1878.
24. Mahon, P.C., Hirota, K., and Semenza, G.L. (2001). FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 15, 2675-2686.
25. Maxwell, P.H., Dachs, G.U., Gleadle, J.M., Nicholls, L.G., Harris, A.L., Stratford, I.J., Hankinson, O., Pugh, C.W., and Ratcliffe, P.J. (1997). Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA 94, 8104-8109.
26. Paige, A.J., Taylor, K.J., Taylor, C., Hillier, S.G., Farrington, S., Scott, D., Porteous, D.J., Smyth, J.F., Gabra, H., and Watson, J.E. (2001). WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc. Natl. Acad. Sci. USA 98, 11417-11422.
27. Pan, C.X., and Koeneman, K.S. (1999). A novel tumor-specific gene therapy for bladder cancer. Med. Hypotheses 53, 130-135.
28. Rathmell, W.K., Hickey, M.M., Bezman, N.A., Chmielecki, C.A., Carraway, N.C., and Simon, M.C. (2004). In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations. Cancer Res. 64, 8595-8603.
29. Ruan, H., Su, H., Hu, L., Lamborn, K.R., Kan, Y.W., and Deen, D.F. (2001). A hypoxia-regulated adeno-associated virus vector for cancer-specific gene therapy. Neoplasia 3, 255-263.
30. Ryan, H.E., Lo, J., and Johnson, R.S. (1998). HIF-1 alpha is required for solid tumor formation and embryonic vasculari-zation. EMBO J. 17, 3005-3015.
31. Semenza, G.L. (2003). Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3, 721-732.
32. Semenza, G.L., Nejfelt, M.K., Chi, S.M., and Antonarakis, S.E. (1991). Hypoxia-inducible nuclear factors bind to an enhancer element located 3 to the human erythropoietin gene. Proc. Natl. Acad. Sci. USA 88, 5680-5684.
33. Semenza, G.L., and Wang, G.L. (1992). A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcrip-tional activation. Mol. Cell Biol. 12, 5447-5454.
34. Takakura, M., Kyo, S., Kanaya, T., Hirano, H., Takeda, J., Yutsudo, M., and Inoue, M.(1999). Cloningofhuman telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res. 59, 551-557.
35. Wang, G.L., and Semenza, G.L. (1993). General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc. Natl. Acad. Sci. USA 90, 4304-4308.
36. Wang, X., Su, C., Cao, H., Li, K., Chen, J., Jiang, L., Zhang, Q., Wu, X., Jia, X., Liu, Y., Wang, W., Liu, X., Wu, M., and Qian, Q. (2008). A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancers. Mol Cancer Ther. 7, 1598-1603.
37. Winnard, P.T., Jr., Botlagunta, M., Kluth, J.B., Mukadam, S., Krishnamachary, B., Vesuna, F., and Raman,V. (2008). Hypoxia-induced human endonuclease G expression suppresses tumor growth in a xenograft model. Cancer Gene Ther. 15, 645-654.
38. Zhang, Y., Ma, H., Zhang, J., Liu, S., Liu, Y., and Zheng, D. (2008). AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice. Life Sci. 82, 1154-1161.
39. Zhao, H.C., Zhang, Q., Yang, Y., Lu, M.Q., Li, H., Xu, C., and Chen, G.H. (2007). p53-expressing conditionally replicative adenovirus CNHK500-p53 against hepatocellular carcinoma in vitro. World J. Gastroenterol. 13, 683-691.